{
 "snapshot": "2026-11-08",
 "note": "Corrections accepted under the corrections policy are appended here with the date, the prior statement, the revised statement, and the evidence that prompted the change.",
 "corrections": [
  {
   "date": "2026-09-04",
   "page": "/best-tirzepatide-providers/ (and every page carrying the committed-vs-month-to-month table)",
   "prior": "Fridays month-to-month tirzepatide rate shown as $240",
   "revised": "Fridays month-to-month rate shown as $359 (about), as the captured source states; $240 is the annual-plan rate",
   "evidence": "The captured 2026-07-20 source text reads 'About $359 month-to-month; about $240/month on annual plan'. The 2026-07-22 build carried the annual rate in both columns."
  },
  {
   "date": "2026-09-04",
   "page": "/providers/nexlife/",
   "prior": "Verdict paragraph stated that mandatory-fee inclusion was not confirmed for NexLife",
   "revised": "Verdict paragraph now matches the record: the captured source states a recurring price with medication included and no separate membership fee (classification verified_all_in)",
   "evidence": "The record's own classification test on the same page; the paragraph was a template error."
  },
  {
   "date": "2026-11-08",
   "page": "/best-tirzepatide-providers/, /editorial-standards/ and every ranking page",
   "prior": "Providers ordered by computed cost only (methodology v1.0), with no editorial score; NexLife shown third on committed cost behind TRYM Health and a program since removed from this site",
   "revised": "Methodology v4.1 (seven weighted categories); NexLife is the editorial #1 pick at 94/100; other providers listed alphabetically pending re-scoring; price tables still sorted by price, and NexLife is not called the lowest",
   "evidence": "Owner methodology change; recorded so the earlier ordering is not silently rewritten"
  },
  {
   "date": "2026-11-08",
   "page": "Site-wide",
   "prior": "Pages described the publication as independent; per-page relationship boxes; NexLife links marked rel=\"sponsored\"; statements that no other company had any relationship with the publisher",
   "revised": "One footer disclosure on every page (affiliate-supported); all outbound links rel=\"nofollow noopener\" with UTM parameters; relationship details being confirmed with the publisher (ownership page)",
   "evidence": "Portfolio disclosure standard"
  },
  {
   "date": "2026-11-08",
   "page": "/research/surmount-2/, /research/, /tirzepatide/, data/trials.json, llms.txt",
   "prior": "SURMOUNT-2 linked to PMID 37385274",
   "revised": "PMID 37385275",
   "evidence": "PubMed: 37385274 is a Lancet comment on SURMOUNT-2; 37385275 is the trial report"
  },
  {
   "date": "2026-11-08",
   "page": "Site-wide price pages",
   "prior": "Prices from the 2026-09-04 dataset; NexLife $169 month to month / $139 on 12 months; Eden $298 with membership; Mochi $278",
   "revised": "November 8, 2026 index: NexLife $129 / $115 (as of 2026-11-06); Eden $129 flat with no membership; Mochi priced per dose; 15 standing-price programs",
   "evidence": "First-party reads 2026-10-15 and 2026-11-08; NexLife 2026-11-06"
  }
 ]
}
